R&D | March 23, 2026
Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Subscribe To Our Newsletter & Stay Updated
